Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 139

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 139
---
 Biopharmaceuticals
that is led by Dr. Charbel Moussa, MBBS, Ph.D. The study is expected to start in the fourth quarter of 2025 and have results available
approximately 12 months thereafter. In addition, the Company will target other clinical indications where it believes JOTROL™
may be effective, which may include indications for Alzheimer’s Disease, Mucopolysaccharidosis Type 1, Friedreich’s ataxia,
and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS).

We have over the past three years received a strong interest in JOTROL™ from various Asian organizations. We believe that this interest has been triggered, in part, because (i) resveratrol is becoming commonly used in Asian herbal medicines as a therapeutic strategy as described in available scientific literature published by PubMed Central: PMCID: PMC7498443 (September 2020); (ii) Hong Kong’s and China’s recent approval of the patent for JOTROL™; (iii) China releasing a list of approximately 120 rare disease indications issued jointly by five national bodies, including the National Health Commission, Ministry of Science and Technology, Ministry of Industry and Information Technology, State Drug Administration, and State Administration of Traditional Chinese Medicine (May 2018), that we believe JOTROL™ can be applicable as a treatment for MPS-1 and MELAS in this population; (iv) recent publications regarding JOTROL™ in the Journal of Alzheimer’s Disease and AAPS Open (Journal of Alzheimer’s Disease 86 (2022) 173-190 February 2022; Kemper et al. AAPS Open June 2022); and (v) the projected increase of the Traditional Chinese Medicine (TCM) market due to several factors which of one is reformulation of existing compounds. We have recently entered into service agreements in the areas of business development, CMC, regulatory affairs and clinical trial management. These agreements are with companies that, we believe, have the knowledge and network in the South-East Asian market to accelerate steps that are needed to have a product that can have treatment value in the territory. The agreements are further described in the section “— Asian Business Development Activities.”

| 78 |

In March 2025, the Company
unveiled a new strategic initiative to introduce Nugevia—a consumer-oriented product line dedicated to longevity and wellness. This
initiative aims to meet the rising demand for